Placing a monetary value on the human health component of zoonotic diseases: A methodological note with an application to cysticercosis in Africa

被引:9
作者
Herrera-Araujo, Daniel [1 ]
Mikecz, Orsolya [2 ]
Pica-Ciamarra, Ugo [2 ]
机构
[1] Univ Paris 09, LEDa, UMR CNRS 8007, UMR IRD 260,PSL, Pl Marechal Lattre de Tassigny, F-75016 Paris, France
[2] Food & Agr Org United Nations, Anim Prod & Hlth Div, Viale Terme Caracalla, I-00153 Rome, Italy
关键词
Zoonotic diseases; Human health; Disability adjusted life years; Value of statistical life; STATISTICAL LIFE; TAENIA-SOLIUM; COST; BURDEN;
D O I
10.1016/j.prevetmed.2019.104862
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Ideally, policies aiming to tackle zoonotic diseases in animals and reduce the burden of disease in humans should be based on an assessment of the cost and benefits of alternative interventions. However, while the cost of actions targeting diseases in animals and humans and the benefits in terms of increased livestock production can be monetized, it is a challenge to monetize improvements in the quality of life or to life expectancy extensions in humans in zoonotic policy evaluations. This paper proposes a method to monetize the human health benefits derived from zoonotic disease reduction and applies it to cysticercosis in Burkina Faso, Egypt, Ethiopia, Kenya, Nigeria and Uganda. We propose a three-step approach to estimate the human health component of the monetary impact of zoonoses. First, we proxy society's willingness to pay to avoid a disability adjusted life year (DALY) using the annualized value of statistical life (VSL) estimated by of the United States Department of Health and Human Services. Second, we implement a benefit transfer methodology to transfer the US value into the context of the sampled countries, accounting for differences in income levels. Finally, we use the 2016 Global Burden of Disease (GBD, 2018) data on cysticercosis to estimate its monetary impact on human health. All results are estimated in current international dollars using purchasing power parity (USD PPP) exchange rates. In the sampled countries, willingness to pay to avoid a DALY is estimated between USD PPP 2 000 and USD PPP 12 700. In most cases, these estimates fall within the range of 1 and 3 times the GDP per capita. The estimated monetary value of the DALYs due to human infections of cysticercosis per 100 000 people ranges between USD PPP 18 000 and USD PPP 98 000 per year. The proposed methodology might represent a first step towards providing a consistent and unbiased measure of the benefits of interventions targeting prevention, detection and control of zoonotic diseases.
引用
收藏
页数:7
相关论文
共 40 条
  • [1] Adler Matthew D, 2006, Yale J Health Policy Law Ethics, V6, P1
  • [2] AfDB, 2017, AFRICAN EC OUTLOOK E
  • [3] Ami D, 2017, REV ECON-FR, V68, P327, DOI 10.3917/reco.683.0327
  • [4] [Anonymous], 2015, Agenda 2063: The Africa We Want A Shared Strategic Framework for Inclusive Growth and Sustainable Development. The first ten-year implementation plan (2014-2023)
  • [5] An implicit price of a DALY for use in a cost-benefit analysis of ARVs
    Brent, Robert J.
    [J]. APPLIED ECONOMICS, 2011, 43 (11) : 1413 - 1421
  • [6] Estimation of the cost of Taenia solium cysticercosis in Eastern Cape Province, South Africa
    Carabin, H.
    Krecek, R. C.
    Cowan, L. D.
    Michael, L.
    Foyaca-Sibat, H.
    Nash, T.
    Willingham, A. L.
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2006, 11 (06) : 906 - 916
  • [7] Cutler D.M., 1997, MICROECONOMICS, V1997, P217, DOI [10.2307/2534757, DOI 10.2307/2534757]
  • [8] Delgado C., 1999, Food, Agriculture and the Environment Discussion Paper - International Food Policy Research Institute
  • [9] PRIORITY SETTING IN GLOBAL HEALTH: TOWARDS A MINIMUM DALY VALUE
    Drake, Tom
    [J]. HEALTH ECONOMICS, 2014, 23 (02) : 248 - 252
  • [10] A QUALITY-OF-LIFE METHOD FOR ESTIMATING THE VALUE OF AVOIDED MORBIDITY
    FRENCH, MT
    MAUSKOPF, JA
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1992, 82 (11) : 1553 - 1555